Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.
ARLINGTON, Va., June 3, 2026 /PRNewswire/ -- Bloomberg Industry Group today announced that it has acquired Regology, a leading AI-powered global regulatory intelligence platform,...
Grid improvements help reduce outages and speed recovery during severe weatherATLANTA, June 3, 2026 /PRNewswire/ -- The Atlantic hurricane season is here and runs...
WASHINGTON, June 3, 2026 /PRNewswire/ -- Digital University (DU) is advancing its mission as the Department of War's (DoW) enterprise training and readiness platform by...
ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...
BERLIN, June 3, 2026 /PRNewswire/ -- NAVEE Commercial returned to Micromobility Europe 2026 with an expanded product ecosystem spanning shared mobility, delivery, energy solutions,...
VÅRGÅRDA, Sweden, June 3, 2026 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, is taking a significant step...
TAIPEI, June 3, 2026 /PRNewswire/ -- AEWIN Technologies' high-performance AI servers and network appliances have been widely deployed by leading cybersecurity providers worldwide to...
YOKOHAMA, Japan, June 3, 2026 /PRNewswire/ -- Visteon Corporation (NASDAQ: VC), a global leader in automotive cockpit electronics, today announced that its 12.3-inch Narrow...